ALZIRAXCopy

• DRUGBANK - Azithromycin
• indication:

  For the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions: <i>H. influenzae</i>, <i>M. catarrhalis</i>, <i>S. pneumoniae</i>, <i>C. pneumoniae</i>, <i>M. pneumoniae</i>, <i>S. pyogenes</i>, <i>S. aureus</i>, <i>S. agal</i>

• pharmacology:

• mechanism:

  Azithromycin binds to the 50S subunit of the 70S bacterial ribosomes, and therefore inhibits RNA-dependent protein synthesis in bacterial cells.

• toxicity:

  Potentially serious side effects of angioedema and cholestatic jaundice were reported

• absorprion:

  Bioavailability is 37% following oral administration. Absorption is not affected by food. Azithromycin is extensively distributed in tissues with tissue concentrations reaching up to 50 times greater than plasma concentrations. Drug becomes concentrated within macrophages and polymorphonucleocytes giving it good activity against Chlamydia trachomatis.

• halflife:

  68 hours

• roouteelimination:

  Biliary excretion of azithromycin, predominantly as unchanged drug, is a major route of elimination.

• volumedistribution:

  * 31.1 L/kg

• clearance:

  * apparent plasma cl=630 mL/min [following single 500 mg oral and i.v. doses]